The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
None
allergy to penicillin,
inability to give informed consent,
concomitant growth of other clinically significant bacteria in blood cultures
neutropenia
Parallel
Penicillin G_1200mg
Drugbenzylpenicillin preferred dosing 1gx4
cloxacillin
Drugcloxacillin 2gx4
Survival at 90 days without any treatment complications
Complications are defined as having any of; relapse within 90 days after treatment finish, need of change or addition of antibiotics due to side effects or treatment failure or adverse events.
Mortality at 90 days
All cause mortality within 90 days from enrollment
Relapse 90 days after end of treatment
Relapse with positive culturing from sterile sites or high suscpition of clinical relapse
Cumulative frequency of side effects within 90 days
all side effects registered as a cumulative frequence
Cumulative frequence of change or addition of antibiotic treatment due to sideeffects or treatment failure
Every time additional antibiotics or change in antibiotic treatment is made due to either side effects or treatment failure (according to treating doctor)
Days with intravenous antibiotics
Differences between treatment groups
Different outcome measures stratified by diagnosis
90 days mortality, relapse 90 days after end of treatment, cumulative side effects stratified by diagnosis
Click on the lead sponsor to view all of their trials.
